Purpose: ABCC2 (MRP2) and ABCG2 (BCRP) transport various endogenous and exogenous compounds, including many anti-cancer drugs, into bile, feces and urine. We investigated the possibly overlapping roles of Abcg2 and Abcc2 in the elimination of the anti-cancer drug methotrexate (MTX) and its toxic metabolite 7-hydroxymethotrexate (7OH-MTX). Experimental Design: We generated and characterized Abcc2;Abcg2 -/-mice, and used these to determine the overlapping roles of Abcc2 and Abcg2 in the elimination of MTX and 7OH-MTX after iv administration of 50 mg/kg MTX. Results: Compared to wild-type, the plasma areas under the curve (AUCs) for MTX were 1.6-fold and 2.0-fold higher in Abcg2 -/-and Abcc2 -/-mice respectively, and 3.3-fold increased in Abcc2;Abcg2 -/-mice. Biliary excretion of MTX was 23-fold reduced in Abcc2;Abcg2 -/-mice, and MTX levels in the small intestine were dramatically decreased. Plasma levels of 7OH-MTX were not significantly altered in Abcg2 -/-mice, but the AUCs were 6.2-fold and even 12.4-fold increased in Abcc2 -/-and Abcc2;Abcg2 -/-mice, respectively. This indicates that Abcc2 compensates for Abcg2 deficiency, but that Abcg2 can only partly compensate for Abcc2 absence. Furthermore, 21-fold decreased biliary 7OH-MTX excretion in Abcc2;Abcg2 -/-mice and substantial 7OH-MTX accumulation in liver and kidney were seen. We additionally found that in absence of Abcc2, Abcg2 mediated substantial urinary excretion of MTX and 7OH-MTX. Conclusions: Abcc2 and Abcg2 together are major determinants of MTX and 7OH-MTX pharmacokinetics. Variation in ABCC2 and/or ABCG2 activity due to polymorphisms or co-administered inhibitors may therefore substantially affect the therapeutic efficacy and toxicity in patients treated with MTX.
Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo INTRODUCTION ABCG2 (BCRP) and ABCC2 (MRP2), both members of the ATP-binding cassette (ABC) transporter superfamily, are present in the apical membranes of hepatocytes and epithelial cells of small intestine and kidney, where they play a role in the excretion of both endogenous and exogenous compounds into bile, feces and urine. They protect the body from a wide range of potentially toxic compounds and influence the pharmacokinetics of many drugs (1) .
ABCG2 and ABCC2 have very broad and substantially overlapping substrate specificities. Examples of xenobiotics that are transported by both ABCG2 and ABCC2 are the anti-cancer drugs doxorubicin, methotrexate, SN-38, and the food-derived carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine) (1) (2) (3) . Furthermore, they can both transport a range of glucuronide and sulphate conjugates of drugs and endogenous compounds (1;3-5) . Many polymorphisms and mutations of ABCG2 and ABCC2 have been identified, often leading to differences in expression and activity (2;6;7). These may partly explain the high inter-patient variability in drug response and occurence of adverse drug reactions, a major concern in the treatment of cancer patients receiving high doses of potentially toxic drugs (2;6;7). Also effective ABCG2 and/or ABCC2 inhibitors (e.g. elacridar, cyclosporin A) are tested in clinical trials to improve treatment (8) . It is therefore important to define the specific and possibly overlapping effects of the different ABC transporters on the pharmacokinetics of (anti-cancer) drugs.
Recently, knockout mouse models for both Abcg2 and Abcc2 have been generated (9) (10) (11) (12) , which have been used extensively for pharmacokinetic analyses of drugs (13;14) . Since ABCG2/Abcg2 and ABCC2/Abcc2 show substantial overlap in substrate specificity, absence of one of them could lead to (partial) functional takeover by the other transporter. This may cause underestimations of the significance of Abcg2 or Abcc2 when the single knockout mice are used. An ABC transporter compound knockout model would allow more detailed investigation, as has recently been shown using other ABC transporter compound knockout mice (9;14-18) .
To study the relative and possibly overlapping physiological and pharmacological functions of Abcg2 and Abcc2 in vivo we have now generated and characterized Abcc2;Abcg2 -/-mice. We used them to analyze overlapping functions of Abcg2 and Abcc2 in determining the iv pharmacokinetics of methotrexate (MTX), a widely used anti-cancer drug and substrate of both transporters (1;3;19) . Since it was recently shown that also 7-hydroxymethotrexate (7OH-MTX), the main (toxic) metabolite of MTX, is transported by both ABCG2 and ABCC2 in vitro (20) , and that absence of Abcc2 in vivo influences 7OH-MTX pharmacokinetics (16) , we additionally investigated the relative impact of both transporters on the pharmacokinetics of 7OH-MTX. We show here that Abcg2 and Abcc2 have additive as well as overlapping functions in determining the pharmacokinetics of MTX and 7OH-MTX. Moreover, Abcg2 and Abcc2 are the main efflux transporters for the biliary excretion of MTX and 7OH-MTX after iv MTX administration and, when Abcc2 is absent, Abcg2 can partly compensate for its loss by mediating significant urinary excretion of MTX and 7OH-MTX.
METHODS

Animals.
Mice were housed and handled according to institutional guidelines complying with Dutch legislation. The generation of Abcc2 -/- (12) and Abcg2 -/-(9) mice has been described. Abcc2;Abcg2 -/-mice were generated by crossbreeding the single knockout strains. All animals were of >99% FVB background and between 9-14 weeks of age. Animals were kept in a temperature-controlled environment with a 12-hour light/12-hour dark cycle. They received a standard diet (AM-II, Hope Farms, Woerden, The Netherlands) and acidified water ad libitum. Western analysis. Preparation of crude membrane fractions and Western blotting were performed as described (21;22) . Equal protein loading was confirmed by Ponceau S staining of the membranes after transfer (not shown). Abcc1, Abcc4, Abcc5 and Abcb11 were detected as described (16) . Abcc3 was detected with mAb M 3 II-18 (dilution 1:100). Bound primary antibodies were detected as described (12;16) . Densitometric analysis was performed using the TINA 2.09 software program (Raytest, Staubenhardt).
Chemicals
RT-PCR analysis. RNA isolation, cDNA synthesis and real-time PCR (RT-PCR) analysis on livers of female mice (n = 3) were done as described (23) .
Vesicular transport assays. ATP-dependent transport of [
3 H]MTX into inside-out vesicles prepared from Sf9 cells overproducing human or murine ABCC2/Abcc2 (24) and control Sf9 cells was determined as described (15) .
Histological, clinical-chemical and hematological analysis. Histological analysis of male and female mouse tissues (n = 6), clinical chemistry analyses (including total and conjugated bilirubin, alkaline phosphatase, aspartate aminotransferase and alanine aminotransferase) on serum of male and female mice (n = 6), and standard hematological analyses of male and female mice (n = 6, twice within a time span of 1.5 years) were performed as described (12) .
Bile and plasma collection for bilirubin analysis. Gall bladder cannulations in male wild-type, Abcg2 -/-, Abcc2
-/-and Abcc2;Abcg2 -/-mice (n = 5-6) and bile and urine collection were performed as described (16;25) . Heparin plasma was collected from male mice (n = 4-6) by cardiac puncture under methoxyflurane anesthesia. To each plasma sample 10 µl of 100 mg/ml ascorbic acid solution in water was added. All samples were frozen immediately and stored at -80°C.
Bilirubin and bile component analysis. Concentrations of bilirubin monoglucuronides, bilirubin diglucuronides and unconjugated bilirubin in bile (100x diluted in water) of the first 15 min fraction, collected urine and plasma were determined as described (26) .
Pharmacokinetic experiments. MTX was administered to female wild-type, Abcg2
-/-and Abcc2;Abcg2 -/-mice (n = 3-13) by injecting 5 µl/g body weight of a 10 mg/ml MTX solution in saline into the tail vein. Animals were killed by terminal bleeding through cardiac puncture under methoxyflurane anesthesia at 7.5, 15, 30, 60 or 120 min after MTX administration and organs were removed.
Biliary MTX excretion experiment. Gall bladder cannulations in female wild-type, Abcg2
-/-and Abcc2;Abcg2 -/-mice (n = 3-5) were performed as described (25) . After successful cannulation, 50 mg/kg MTX was administered iv as described above. Bile was collected in 15 min fractions for 60 min. Mice were killed by cardiac puncture and blood and organs were collected. Small intestinal tissue and contents were separated. -/-mice (n = 5-9) were individually housed in Ruco Type M/1 stainless steel metabolic cages (Valkenswaard, The Netherlands). They were allowed 24 hours to adapt before 50 mg/kg MTX was injected into the tail vein as described above. Feces and urine were collected for 24 hours.
HPLC analysis of MTX and 7OH-MTX. Collected organs were homogenized in an ice-cold 4% BSA solution and plasma and bile were diluted in human plasma before HPLC analysis. Urine was diluted in water, feces were homogenized in ice-cold 4% BSA solution. MTX and 7OH-MTX concentrations in the different matrices were determined as described (27) . Statistical analysis. Unless otherwise indicated, the two-sided unpaired Student's ttest was used to assess the statistical significance of differences between wild-type and knockout mice. When differences between more than 2 groups were analyzed, one-way ANOVA followed by Tukey's multiple comparison test was performed, as indicated. Results are presented as means ± standard deviations (SD). Differences were considered statistically significant when P < 0.05. Averaged concentrations for each time point were used to calculate the area under the plasma concentration versus time curve (AUC) from t = 0 to the last sampling point by the linear trapezoidal rule; standard errors (SE) were calculated by the law of propagation of errors (28) .
RESULTS
Macroscopic and microscopic analysis of Abcc2;Abcg2 -/-mice. Abcc2;Abcg2 -/-mice were viable, fertile and had normal life spans and body weights. Macroscopic and microscopic histological and pathological analysis did not reveal obvious specific aberrations in tissues of the Abcc2;Abcg2 -/-mice, including the liver. Similar to what was previously shown for Abcc2 -/-mice (12), the liver weight of Abcc2;Abcg2 -/-mice was significantly (26-36%) increased compared to wild-type ( Figure 1A ), but not significantly different from that of Abcc2 -/-mice (ANOVA), suggesting that the increase in liver weight is primarily caused by Abcc2 absence.
Protein expression of other ABC transporters in tissues of Abcc2;Abcg2 -/-mice. Absence of both Abcg2 and Abcc2 in tissues of the double knockout mice may lead to compensatory increases in expression of other ABC transporters. Therefore we analyzed the expression of Abcc1 (Mrp1), Abcc3 (Mrp3), Abcc4 (Mrp4), Abcc5 (Mrp5) and Abcb11 (Bsep) in tissues of Abcc2;Abcg2 -/-mice (>99% FVB background). Abcc3 protein levels in liver (but not kidney (not shown)) of male (not shown) and female (Figure 1B) Abcc2;Abcg2 -/-mice were ~1.7-fold increased compared to wild-type. Abcc4 protein in female liver and kidney ( Figures 1C and D ) and male kidney (not shown) of Abcc2;Abcg2 -/-mice was ~1.5-fold increased. Abcc4 in male liver was very low in both wild-type and Abcc2;Abcg2 -/-mice (not shown). Abcc1 in male liver and Abcc5 in male and female liver were quite low and not different between wild-type and Abcc2;Abcg2 -/-mice (not shown). Abcb11 expression was not increased in Abcc2;Abcg2 -/-mice, and possibly even mildly decreased compared to wild-type (not shown). Combined, the expression patterns of Abcc3 and Abcc4 in liver and kidney of Abcc2;Abcg2 -/-mice were similar to what was found for Abcc2 -/-mice in >99% FVB background (12) , suggesting that these inductions are mainly the result of absence of Abcc2. Abcc2;Abcg2 -/-mice (means ± SD, n = 5-6, **, P < 0.01, ***, P < 0.001 compared to wildtype, ANOVA). B, protein levels of Abcc3 in crude membrane fractions of liver samples from two independent female wild-type and Abcc2;Abcg2 -/-mice. Densitometric analysis of the blots showed that on average Abcc3 expression was 1.7-fold increased in Abcc2;Abcg2 -/-mice. C, protein levels of Abcc4 in crude membrane fractions of liver samples from two independent female wild-type and Abcc2;Abcg2 -/-mice. Densitometric analysis of the blots showed that on average Abcc4 expression was 1.5-fold increased in Abcc2;Abcg2 -/-mice. D, protein levels of Abcc4 in crude membrane fractions of kidney samples from two independent female wild-type and Abcc2;Abcg2 -/-mice. Densitometric analysis of the blots showed that on average Abcc4 expression was 1.6-fold increased in Abcc2;Abcg2 -/-mice.
Equal protein loading was confirmed by Ponceau S staining of the membranes after transfer. In C and D, the lane with the positive control (Sf-9 vesicles containing ABCC4 (49)), is indicated with "+". Underglycosylation of ABCC4 in the Sf-9 cells causes the faster migration compared to the murine Abcc4. The amount of protein loaded in each lane is noted above the respective lanes.
Expression levels of genes involved in methotrexate disposition.
Since we wanted to analyze the pharmacokinetics of MTX in Abcc2;Abcg2 -/-mice, we determined mRNA expression levels of genes that may be involved in MTX metabolism and transport in livers of female knockout mice. We found that mRNA levels of aldehyde oxidase 1 and 3, which are implicated in the conversion of MTX to 7OH-MTX (29) were 3-8-fold increased in livers of Abcc2 -/-and Abcc2;Abcg2 -/-mice (Figures S1A and S1B). mRNA levels of the uptake transporter Slco1a4 were not different from wild-type in the knockout strains ( Figure S1C ). mRNA of Slco1b2 was ~2-fold increased in Abcc2 -/-and Abcc2;Abcg2 -/-mice ( Figure S1D ).
Plasma clinical chemistry and hematological analysis of Abcc2;Abcg2 -/-mice. Except for bilirubin (see below), standard plasma clinical chemistry parameters were not significantly different between any of the strains analyzed (not shown). Hematological analysis of male and female Abcc2;Abcg2 -/-mice showed a tendency of reduced hemoglobin levels as was previously seen in Abcc2 -/-mice in a mixed genetic background (12) (not shown). Other measured parameters did not consistently show differences with wild-type mice (not shown).
Bilirubin in plasma, bile and urine of Abcc2;Abcg2 -/-mice. We have previously shown that Abcc2 -/-mice had mildly increased plasma levels of conjugated bilirubin due to reduced biliary excretion of this compound (12) . In Abcg2 -/-mice on the other hand, the plasma levels of unconjugated bilirubin were increased (9) . Clinical chemistry (not shown) and subsequent HPLC analysis ( Figure  2A ) of plasma confirmed these findings. In Abcc2;Abcg2 -/-mice, bilirubin monoglucuronide, diglucuronide and unconjugated bilirubin concentrations were all increased, leading to 7-fold higher total bilirubin plasma levels in Abcc2;Abcg2 -/-mice compared to wild-type.
Because Abcg2 and Abcc2 both excrete their substrates into bile, we analyzed bile flow and biliary bilirubin output in the different strains. Like in Abcc2 -/-mice (12), the cumulative bile flow over 1 hour in Abcc2;Abcg2 -/-mice was significantly reduced, to 54% of wild-type bile flow and not significantly different from Abcc2 -/-mice (ANOVA) ( Figure 2B ). The total biliary bilirubin output in Abcg2 -/-mice was comparable to wild-type ( Figure 2C ). As shown before (11;12), the total biliary bilirubin excretion of Abcc2 -/-mice was significantly reduced, due to a decreased bilirubin monoglucuronide output. This was also seen in Abcc2;Abcg2 -/-mice. Biliary bilirubin diglucuronide excretion in wild-type mice was very low, and in Abcg2 -/-mice this was not detected at all. As shown before (16) , biliary excretion of bilirubin diglucuronide was significantly increased in Abcc2 -/-mice. This was similar for Abcc2;Abcg2 -/-mice and is apparently related to Abcc2 absence. Biliary excretion of unconjugated bilirubin was modest in wild-type and Abcc2 -/-mice, and not significantly different ( Figure 2C ). In Abcg2 -/-and Abcc2;Abcg2 -/-mice however, the biliary unconjugated bilirubin excretion was significantly reduced. In urine collected from the gall bladder cannulated mice, bilirubin monoglucuronide was detected only in Abcc2 -/-and Abcc2;Abcg2 -/-mice ( Figure  2D ), reflecting the increased bilirubin monoglucuronide plasma levels in these strains (Figure 2A) . Bilirubin diglucuronides or unconjugated bilirubin were not detected in the urine of any of the strains. -/-, Abcc2 -/-and Abcc2;Abcg2 -/-mice. A, total bilirubin, bilirubin monoglucuronide (BMG), bilirubin diglucuronide (BDG) and unconjugated bilirubin (UCB) concentrations in plasma of the various mouse strains (nq, not quantifiable, detection limit 0.3 µM). B, bile flow in the various mouse strains. Bile was collected by gall bladder cannulation in 15 min fractions over 1h. C, output of total bilirubin, bilirubin monoglucuronide (BMG), bilirubin diglucuronide (BDG) and unconjugated bilirubin (UCB) into the bile of the various mouse strains. Bile collected in the first 15 min after gall bladder cannulation was analyzed for bilirubin concentration (nq, not quantifiable, detection limit 0.05 µM). D, bilirubin monoglucuronide (BMG) concentration in urine of gall bladder cannulated mice (nq, not quantifiable, detection limit 0.05 µM). Data are means ± SD (n = 4-6, *, P < 0.05, **, P < 0.01, ***, P < 0.001, Student's t-test).
Functionally overlapping roles of Abcg2 and Abcc2 in the elimination of methotrexate. It was shown previously using Abcg2 -/-and Abcc2 -/-mice that both ABC transporters play a significant role in plasma elimination of ([ 3 H])MTX after iv administration (12;16;30) . However, whereas transport of MTX by murine Abcg2 in vitro has been shown before (19) , direct transport by murine Abcc2 has not. We therefore investigated transport of [ 3 H]MTX using Sf9-vesicles expressing murine Abcc2 (24) . We found that, like human ABCC2, murine Abcc2 actively transports MTX ( Figure 2S ). To investigate the relative roles of Abcc2 and Abcg2 in MTX pharmacokinetics, we administered MTX iv (50 mg/kg) to the different strains, and measured plasma and tissue concentrations over 120 min. The plasma AUCs for Abcg2 -/-and Abcc2 -/-mice were 1.6-and 2.0-fold increased compared with wild-type, respectively ( Figure 3A , Table 1S ). In Abcc2;Abcg2 -/-mice the plasma AUC was 3.3-fold increased, suggesting additive effects of Abcg2 and Abcc2 on MTX plasma elimination.
MTX liver concentrations were, like plasma, highest (44-54% of the dose) early after administration and decreased quite rapidly thereafter ( Figure 3B , Table  1S ). As shown before for Abcc2 -/-mice (16), and despite increased Slco1b2 expression (Figure 1SD ), the liver-to-plasma ratios over 120 min ( Figure 3C ) were significantly reduced in Abcc2 -/-and Abcc2;Abcg2 -/-mice. The liver-to-plasma ratios of Abcg2 -/-mice over 120 min were not significantly different from wild-type. This suggests more effective liver elimination of MTX towards plasma (over the sinusoidal membrane of hepatocytes), most likely via (upregulated) Abcc3 (16) . This may contribute to the increased plasma concentrations of MTX in both Abcc2 -/-and Abcc2;Abcg2 -/-mice compared to wild-type. Note that Abcc3 was not upregulated in single Abcg2 -/-mice (not shown), consistent with liver-to-plasma MTX ratios being similar to wild-type values.
The small intestinal tissue and contents levels of MTX between 7.5 and 60 min ( Figure 3D , Table 1S ) were significantly reduced compared to wild-type in Abcg2
-/-and Abcc2;Abcg2 -/-mice at every measured time point. Whereas in Abcg2 -/-and Abcc2 -/-mice still substantial MTX excretion into the small intestine was observed, in Abcc2;Abcg2 -/-mice this was virtually absent, and significantly lower than in the Abcg2 -/-and Abcc2 -/-mice 60 min after administration (P < 0.01, ANOVA). This shows that Abcg2 and Abcc2 together dictate the excretion of MTX into the small intestine and that they partly compensate for each other's absence.
To investigate the functions of Abcg2 and Abcc2 in more detail, we measured their influence in biliary excretion and/or direct intestinal MTX excretion with gall bladder cannulation experiments. Figure 4A shows that Abcc2 and Abcg2 both influence the biliary excretion of MTX and that each can partly compensate for loss of the other. In the Abcc2;Abcg2 -/-mice, the biliary excretion of MTX was dramatically reduced, to only 2 ± 1% of the dose versus 45 ± 20% in wild-type (P = 0.011), showing that Abcg2 and especially Abcc2 are the main determinants for biliary excretion of MTX.
As shown before (16), MTX levels in small intestinal tissue and contents of the gall bladder cannulated mice were low (<3% of the dose) compared to the biliary MTX levels, suggesting that direct intestinal excretion is not important in MTX elimination. Surprisingly, whereas the plasma concentrations after this experiment ( Figure 3SA) were not significantly different from wild-type in any of the knockout strains (ANOVA), ~3-fold increased levels of MTX in the small intestinal contents of Abcc2;Abcg2 -/-mice compared to the other mouse strains were found (P < 0.05, ANOVA) ( Figure 4B ), suggesting the presence of an active direct intestinal MTX excretion mechanism in Abcc2;Abcg2 -/-mice which is not present/active in the other strains. Figure 4C shows the role of Abcg2 and Abcc2 in the urinary and fecal excretion of MTX the first 24 hr after iv administration (50 mg/kg). As described before (16) , MTX urinary excretion in Abcc2 -/-mice was significantly increased compared to wild-type mice, thereby reflecting increased plasma and kidney levels. In Abcg2 -/-and Abcc2;Abcg2 -/-mice however, despite 1.6-fold and 3.3-fold increased plasma AUCs and increased kidney concentrations of MTX ( Figure 3A, Table 1S ), the urinary excretion of MTX was not different from wild-type mice. This suggests that Abcg2 in the kidney is (at least partly) responsible for the increased urinary excretion of MTX in Abcc2 -/-mice. Fecal excretion of MTX over 24 hr was not significantly different from wild-type mice in any of the knockout strains. Figure 3S . C, urinary (left panel) and fecal (right panel) excretion in the first 24 hrs after iv administration to mice of the various strains (n = 5-9). Data are presented as means ± SD (*, P < 0.05, **, P < 0.01, ANOVA).
Functionally overlapping roles of Abcg2 and Abcc2 in the elimination of 7OH-MTX. ABCG2 and ABCC2 can transport 7OH-MTX, the main toxic metabolite of MTX, in vitro (20) . Furthermore, Abcc2 influences 7OH-MTX pharmacokinetics in vivo (16) . The Abcc2;Abcg2 -/-mice were therefore used to analyze the relative roles of both transporters in the pharmacokinetics of 7OH-MTX after iv administration of MTX ( Figure 5 , Table 2S ). As shown before (16), Abcc2 -/-mice have a 6.2-fold increased 7OH-MTX plasma AUC compared to wild-type ( Figure 5A , Table 2S ). In Abcg2 -/-mice on the other hand, the 7OH-MTX plasma AUC was not significantly different from wild-type, which would suggest that Abcg2 is not important for 7OH-MTX elimination in vivo. However, in Abcc2;Abcg2 -/-mice the 7OH-MTX plasma AUC was 12.4-fold higher than in wild-type mice and 2.0-fold higher compared to Abcc2 -/-mice (P = 0.03, Student's t-test). This shows that when Abcc2 is absent, Abcg2 does influence the elimination of 7OH-MTX from the circulation. Already 7.5 min after MTX administration the 7OH-MTX liver levels ( Figure  5B ) were relatively high in all strains and significantly higher in Abcc2 -/-and Abcc2;Abcg2 -/-mice compared to wild-type, suggesting a rapid 7OH-MTX formation in the liver, which may even have been increased compared to wild-type in Abcc2-deficient mice due to overexpression of aldehyde oxidase 1 and 3 in livers of these mice ( Figure 1S ). Whereas in Abcc2 -/-mice the 7OH-MTX liver levels decreased rapidly after 30 min (Figure 5B ), the liver levels in Abcc2;Abcg2 -/-mice stayed relatively high up to 60 min after administration, suggesting initially delayed elimination of 7OH-MTX from the liver in the Abcc2;Abcg2 -/-mice. There was little difference between Abcg2 -/-and wild-type mice in 7OH-MTX small intestinal tissue and contents levels ( Figure 5C ), suggesting only a minor role for Abcg2 in the elimination of 7OH-MTX via the small intestine. As shown before (16) , in the Abcc2 -/-mice the small intestinal 7OH-MTX levels were markedly lower compared to wild-type at every time point ( Figure 5C ). In Abcc2;Abcg2 -/-mice the small intestinal levels of 7OH-MTX were even more reduced, to only 11% of wild-type levels at 60 min (P = 3.1*10 -5 ), suggesting that when Abcc2 is absent, Abcg2 is involved in excretion of 7OH-MTX into the small intestine, most likely via biliary excretion (see below).
7OH-MTX related toxicity in patients is suggested to mainly occur in the kidney, leading to renal failure (31;32). Therefore we analyzed the kidney levels of 7OH-MTX after iv administration of MTX ( Figure 5D ). These in general followed the plasma levels of 7OH-MTX. Thus, in Abcc2 -/-and in Abcc2;Abcg2 -/-mice they were significantly increased, up to 11-fold and 35-fold compared to wild-type mice at 60 min.
The effect of Abcg2 and Abcc2 on the biliary excretion of 7OH-MTX after iv injection of MTX is shown in Figure 6A . Clearly, Abcc2 is the main determinant for the biliary excretion of 7OH-MTX, but in the absence of Abcc2, Abcg2 can (partly) take over its function. In Abcc2;Abcg2 -/-mice, despite increased liver levels ( Figure  5B ), the biliary 7OH-MTX output was decreased to only 5% of wild-type output (0.12 ± 0.04% versus 2.51 ± 1.53% of the dose, P = 0.04), illustrating the important role for both transporters in the biliary excretion of 7OH-MTX. The levels of 7OH-MTX in the small intestinal tissue and contents 60 min after MTX administration in the gall bladder cannulation experiment were negligible (not shown), indicating that direct intestinal excretion is not important for 7OH-MTX elimination.
The urinary excretion of 7OH-MTX during the first 24 hr after iv administration of MTX ( Figure 6B ) was quite low and not significantly different from wild-type in Abcg2 -/-mice. As shown before (16) , urinary excretion of 7OH-MTX was significantly increased in Abcc2 -/-mice. Although in Abcc2;Abcg2 -/-mice the urinary excretion of 7OH-MTX was significantly higher compared with wild-type, it was lower than in Abcc2 -/-mice (n = 5-9, P < 0.001, ANOVA). As the AUC plasma of 7OH-MTX in the Abcc2;Abcg2 -/-mice was 2-fold higher than in the Abcc2 -/-mice ( Figure 5A ), this suggests that Abcg2 is (at least partly) responsible for the urinary excretion of 7OH-MTX in the Abcc2 -/-mice. The fecal excretion of 7OH-MTX was very low in all strains (<3% of the dose) and difficult to determine due to endogenous background peaks (not shown). Figure 3S . B, 7OH-MTX urinary excretion in the first 24 hrs after iv administration of MTX to mice of the various strains (n = 6-9, *, P < 0.05, ***, P < 0.001, ANOVA). Data are presented as means ± SD.
DISCUSSION
To investigate the possibly overlapping roles of Abcg2 and Abcc2 in the elimination of shared endogenous and exogenous substrates in vivo, we generated Abcc2;Abcg2 -/-mice, which are viable and fertile. The spontaneous phenotypes of the double knockout mice appear to be a combination of what we observed previously for Abcg2 -/-and Abcc2 -/-mice (9;12), suggesting separate roles of Abcg2 and Abcc2 in most physiological functions. We show here that Abcg2 and Abcc2 play functionally overlapping roles in the elimination of the anti-cancer drug MTX and its toxic metabolite 7OH-MTX. We conclude that Abcc2;Abcg2 -/-mice are quite healthy overall and can be used to study overlapping Abcg2 and Abcc2 functions in vivo.
It was shown previously that in Abcg2 -/-mice unconjugated bilirubin plasma levels were mildly increased (9), whereas in Abcc2 -/-mice conjugated bilirubin plasma levels were increased (11;12) . This was confirmed in the present study using HPLC. In the Abcc2;Abcg2 -/-mice a combination of both was observed: 7-fold increased plasma concentrations of total bilirubin, due to significantly increased unconjugated as well as conjugated bilirubin. This is probably the consequence of reduced biliary excretion of conjugated and unconjugated bilirubin in the Abcc2;Abcg2 -/-mice. Combined, this suggests that Abcc2 is mainly involved in biliary excretion of bilirubin monoglucuronides, whereas Abcg2 excretes unconjugated bilirubin. However, if Abcg2 transports unconjugated bilirubin, it clearly has a low efficiency, as the amount excreted into bile is very small, also in wild-type mice. Even in Gunn rats, which have elevated serum unconjugated bilirubin due to absence of the conjugating enzyme UGT1A1, very little is excreted into bile (33) . An alternative explanation for the observed changes is decreased unconjugated bilirubin uptake into the liver of Abcg2-deficient mice. An uptake system for unconjugated bilirubin in mice has, however, not been unambiguously identified yet (34) , making this difficult to investigate. Note that in Abcc2;Abcg2 -/-mice still substantial biliary output of conjugated bilirubin is present, suggesting that an alternative canalicular transport mechanism transports bilirubin into bile. Nevertheless, the increased bilirubin plasma levels in the Abcc2;Abcg2 -/-mice are still relatively low compared to normal bilirubin plasma levels in humans (5-30 µM). It is therefore unlikely that plasma bilirubin levels would markedly influence drug pharmacokinetics in these mice.
We have studied the overlapping roles of Abcc2 and Abcg2 in plasma-and tissue pharmacokinetics of MTX and 7OH-MTX. The MTX plasma pharmacokinetics in the different strains revealed additive effects of Abcg2 and Abcc2. As MTX-related toxicity and outcome in patients after high-dose MTX therapy appear to correlate with MTX serum levels (35-37), differences in expression or activity of ABCG2 and/or ABCC2 may have profound effects on MTX-induced toxicity in patients. Since many known ABCC2 and ABCG2 polymorphisms drastically reduce, or even abrogate the function of these proteins (2;6;7), this could be an important contributory factor to variable MTX efficacy and toxicity in patients. Interestingly, in psoriasis-patients treated with MTX, SNPs in ABCG2 were associated with a good response to therapy (38) .
For the plasma pharmacokinetics of 7OH-MTX after MTX administration, we found Abcc2 to be the main determinant. Nevertheless, when Abcc2 is absent, Abcg2 still plays a significant role. This was best illustrated by the 12.4-fold increased 7OH-MTX plasma AUC in Abcc2;Abcg2 -/-mice, versus 6.2-fold in Abcc2 -/-mice. Table 3S provides an overview of the overall excretion of MTX and 7OH-MTX in the strains analyzed. Analysis of the biliary excretion of MTX and 7OH-MTX revealed that Abcg2 and Abcc2 together dictate these processes. Abcc2 was the most important transporter in biliary excretion of both compounds after iv MTX administration. Although mRNA levels of aldehyde oxidase were increased in both Abcc2-deficient strains (Figure 1S ), the hepatic MTX levels in these strains were not significantly different from wild-type levels. The reduced biliary excretion of MTX must therefore primarily be caused by reduced Abcc2/Abcg2-mediated transport of MTX into bile, and not by increased conversion of MTX to 7OH-MTX.
It is interesting to note that males have higher hepatic Abcg2 levels than females (39) . As our experiments were performed in female mice the effect of Abcg2 in the male liver may be underestimated here. Still, a clear effect of Abcg2 on biliary excretion in female Abcc2 -/-mice could be demonstrated, both for MTX and 7OH-MTX. This was reflected by drastically decreased levels of both compounds in the small intestine and its contents of Abcc2;Abcg2 -/-mice. Interestingly, Rau et al. (2006) (40) found an association between a frequent ABCC2 polymorphism and MTX pharmacokinetics, but only in females. This suggests that, as Abcg2 apparently can (partly) compensate for Abcc2 absence, in males ABCG2 expression is sufficient for effective compensatory MTX excretion, whereas in females it is not.
MTX-related toxicity in humans is often seen in bone marrow and the gastrointestinal tract, although this is generally rendered manageable by coadministration of leucovorin. As Abcc2 and Abcg2 are primarily responsible for the biliary excretion of MTX and 7OH-MTX, reduced expression or activity of ABCC2 and/or ABCG2 in patients may cause reduced biliary excretion of MTX and 7OH-MTX. This could lead to reduced exposure of the intestine to these compounds after iv administration, and therefore to reduced gastrointestinal toxicity.
Besides bone marrow and gastrointestinal toxicity, high-dose MTX treatment in patients may result in renal failure (41) . This is thought to be caused by precipitation of MTX and especially 7OH-MTX, which is highly insoluble, in kidney tubules (31;32) . As shown before (16) , the urinary output of MTX and 7OH-MTX in Abcc2 -/-mice was significantly increased compared to wild-type in the first 24 hrs after MTX administration. Although in the Abcc2;Abcg2 -/-mice the plasma AUCs for MTX and 7OH-MTX were even higher than in the Abcc2 -/-mice, the urinary excretion of both compounds was reduced compared to Abcc2 -/-mice and comparable to wild-type. This suggests that in Abcc2 -/-mice, the increased urinary excretion of MTX and 7OH-MTX is mediated through Abcg2 in the kidney. Furthermore, whereas the Abcg2 -/-mice had (like the Abcc2 -/-mice) increased plasma MTX levels, they did not show increased urinary MTX excretion. This suggests that even in the wild-type situation Abcg2 may be involved in urinary MTX excretion. These findings are in line with the previously described effect of Abcg2 on the urinary excretion of another Abcg2 substrate, E3040S (42) .
Given the increased kidney levels and urinary output of MTX and 7OH-MTX in Abcc2-deficient mice, reduced ABCC2 expression/activity may be a risk factor for kidney toxicity, which is primarily due to precipitation of these compounds in the urine (31;32) . Interestingly, renal failure after high-dose MTX treatment in a patient with an ABCC2-mutation has been reported (43) . In contrast, as Abcg2 appears to mediate excretion of MTX and especially 7OH-MTX into urine, one could speculate that decreased activity of ABCG2 may decrease the risk of nephrotoxicity after MTX treatment.
Since Abcc4 protein was 1.5-fold increased in the kidneys of Abcc2 -/-and Abcc2;Abcg2 -/-mice ( Figure 1D , (12)), we cannot exclude a minor contribution of Abcc4 overexpression on the increased urinary excretion of MTX and/or 7OH-MTX in Abcc2-deficient mice. However, this does not explain the differences in urinary excretion between Abcc2 -/-and Abcc2;Abcg2 -/-mice, as both strains had increased kidney Abcc4. If any, the effects of increased Abcc4 on the urinary MTX and 7OH-MTX excretion are very small compared to the effect of Abcg2.
It should be noted that the iv bolus injection of 50 mg/kg MTX administered here is comparable to a dose of 154 mg/m 2 in man (12;44), which is relatively low for high-dose cancer treatment, as doses of up to 12 g/m 2 are given (29) . Whether the effects of Abcc2 and/or Abcg2 found here are also valid for higher doses or longer infusion times remains to be elucidated. Interestingly, associations between ABCC2 and ABCG2 mutations/polymorphisms and MTX-pharmacokinetics or toxicities in patients were found previously after high-dose (1-5 g/m 2 ) MTX infusions (40;43;45) , suggesting that our results are also relevant for higher doses and longer infusions.
Of course, as always, extrapolating data from mice to humans should be done with caution. For example, in humans, biliary excretion of MTX appears somewhat less important (up to 20% of the dose is excreted into bile, although this was measured in very few patients (46;47)), whereas urinary excretion of MTX appears somewhat more important compared to mice (46) . Furthermore, other MTX/7OH-MTX transporters in human liver or kidney may be more significant in humans than in mice.
Overall, our data show that Abcg2 and Abcc2 are important transporters for plasma elimination as well as biliary and urinary excretion of MTX and its toxic metabolite 7OH-MTX. When one is absent, the other can (at least partly) compensate for its loss. These findings provide direct explanations for previously found correlations between ABCC2 and ABCG2 polymorphisms/mutations and MTX pharmacokinetics or toxicity in patients (38;40;43;48) , and show the potential value of Abcc2;Abcg2 -/-mice for studying the pharmacokinetics of endogenous and exogenous compounds in vivo. Table 1S . Levels of MTX in tissues and plasma of female wild-type, Abcg2 -/-, Abcc2 -/-and Abcc2;Abcg2 -/-mice at different time points after iv administration of 50 mg/kg MTX.
Note: MTX tissue levels are expressed as percentage of the dose (means ± SD, n = 3-9) and MTX plasma levels are presented as µg/ml (means ± SD, n = 3-12). * P < 0.05, ** P<0.01, *** P< 0.001 compared to wild-type mice at the same time point (Student's t-test was used for statistical analysis). Table 2S . Levels of 7OH-MTX in tissues and plasma of female wild-type, Abcg2 -/-, Abcc2 -/-and Abcc2;Abcg2 -/-mice at different time points after iv administration of 50 mg/kg MTX.
Note: 7OH-MTX tissue levels are expressed as percentage of the MTX dose (means ± SD, n = 3-9) and 7OH-MTX plasma levels are presented as µg/ml (means ± SD, n = 3-12). *P < 0.05, ** P < 0.01, *** P < 0.001, compared to wild-type mice at the same time point (Student's ttest was used for statistical analysis). Table 3S . Excretion of MTX and 7OH-MTX in female wild-type, Abcg2 -/-, Abcc2 -/-and Abcc2;Abcg2 -/-mice after iv administration of 50 mg/kg MTX.
Note: Excretion is given as % of the administered dose. Biliary and direct intestinal (small intestinal contents) excretion were determined in the first 60 min after iv administration of MTX to anesthetized, gall bladder cannulated mice (n = 3-5, see Methods). Urinary and fecal excretion were determined over the first 24 hr after iv administration of MTX to unanesthetized mice (n = 5-9, see Methods). Data are presented as means ± SD, * P < 0.05, ** P < 0.01, *** P < 0.001, compared to wild-type mice in the same experiment (Student's t-test was used for statistical analysis). ↑, increased compared to wild type, ↓, decreased compared to wild type, nd, not detected (background in this matrix was too high for reliable quantification). 
